Stoke Therapeutics, Inc. (STOK): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biotech company tackles severe diseases at their core? Stoke Therapeutics, Inc. (STOK), a Nasdaq-listed company, is dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. But how exactly did they get here, who's steering the ship, and what's their master plan for making a difference (and a profit)? Keep reading to discover the fascinating details behind Stoke Therapeutics' history, ownership, mission, and innovative approach to changing lives.

Stoke Therapeutics, Inc. (STOK) History

Stoke Therapeutics, Inc. Founding Timeline

Year established

The company was established in 2014.

Original location

The company is headquartered in Bedford, Massachusetts.

Founding team members

The founding team included individuals with expertise in RNA biology and drug development. Key figures include:

• Adrian R. Krainer, Ph.D.: A pioneer in RNA splicing research, his work provided the scientific foundation for the company's technology.
• Isabelle Lousada: Served as the founding Chief Executive Officer.

Initial capital/funding

In 2015, the company secured a $40 million Series A financing round led by Apple Tree Partners, with participation from RTW Investments and Aisling Capital.

Stoke Therapeutics, Inc. Evolution Milestones

Stoke Therapeutics, Inc. Transformative Moments

• Platform Technology Development: The development of the TANGO platform was a transformative moment, enabling the company to target the underlying cause of genetic diseases by upregulating protein expression.
• Clinical Validation of STK-001: Advancing STK-001 into clinical trials and demonstrating early positive data provided validation of the company's approach and attracted significant investor interest.
• Strategic Partnerships: Forming strategic partnerships with other pharmaceutical companies or research institutions could provide additional resources and expertise to accelerate drug development and expand the company's pipeline.

To gain more insights into the company's financial performance, consider exploring: Breaking Down Stoke Therapeutics, Inc. (STOK) Financial Health: Key Insights for Investors

Stoke Therapeutics, Inc. (STOK) Ownership Structure

The ownership structure of Stoke Therapeutics, Inc. reflects a mix of institutional, insider, and retail investors, all playing a role in the company's financial ecosystem. Understanding this structure provides insights into the company's governance and strategic decision-making processes. For more in-depth information, check out: Exploring Stoke Therapeutics, Inc. (STOK) Investor Profile: Who’s Buying and Why?

Stoke Therapeutics, Inc.'s Current Status

Stoke Therapeutics, Inc. is a public company, trading on the NASDAQ under the ticker symbol STOK. This means that shares of the company are available for purchase by the general public, and the company is subject to regulations and reporting requirements set forth by the U.S. Securities and Exchange Commission (SEC).

Stoke Therapeutics, Inc.'s Ownership Breakdown

As of April 2025, the ownership of Stoke Therapeutics, Inc. is distributed among various types of shareholders. Here's an approximate breakdown:

Stoke Therapeutics, Inc.'s Leadership

The leadership team at Stoke Therapeutics, Inc. is responsible for guiding the company's strategic direction and overseeing its operations. Key members of the leadership team include:

• Edward M. Kaye, M.D.: Chief Executive Officer
• Barry Ticho, M.D., Ph.D.: Chief Medical Officer
• Peter Griffin, Ph.D.: Chief Scientific Officer
• Arthur T. Suckow: Chief Financial Officer

These individuals, along with other members of the executive team, bring a wealth of experience and expertise to Stoke Therapeutics, Inc., helping to drive the company's mission and achieve its strategic goals.

Stoke Therapeutics, Inc. (STOK) Mission and Values

Stoke Therapeutics is dedicated to addressing the underlying causes of severe genetic diseases by developing medicines that augment protein expression. The company focuses on providing hope for patients and families affected by genetic conditions.

Stoke Therapeutics' Core Purpose

Official mission statement

Stoke Therapeutics' mission statement is: 'To develop medicines that increase gene expression to treat the underlying cause of severe genetic diseases.'

• Focuses on developing treatments for severe genetic diseases.
• Aims to address the root cause of these diseases by enhancing protein expression.
• Dedicated to bringing hope to patients and families impacted by genetic conditions.

Vision statement

While a specific, formal vision statement is not explicitly available, Stoke Therapeutics' vision can be inferred from their actions and goals:

• To become a leader in developing RNA-based medicines that target the underlying causes of genetic diseases.
• To expand the application of their TANGO (Targeted Augmentation of Nuclear Gene Output) platform to a wide range of genetic disorders.
• To transform the lives of patients and families affected by severe genetic conditions by providing innovative and effective treatments.

Company slogan/tagline

Stoke Therapeutics does not have a prominently advertised official slogan or tagline. However, their core focus and mission imply a consistent message:

• Implied Tagline: 'Unlocking the Power of RNA to Treat Genetic Diseases.'
• Reflects their commitment to developing innovative RNA-based therapies.
• Emphasizes their goal of addressing the underlying causes of genetic diseases to improve patient outcomes.

To gain more insights into Stoke Therapeutics, Inc. (STOK), consider reading: Exploring Stoke Therapeutics, Inc. (STOK) Investor Profile: Who’s Buying and Why?

Stoke Therapeutics, Inc. (STOK) How It Works

Stoke Therapeutics is a biotechnology company pioneering a new approach to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. The company develops antisense oligonucleotide (ASO) medicines that target RNA to increase protein production.

Stoke Therapeutics' Product/Service Portfolio

Stoke Therapeutics' Operational Framework

Stoke Therapeutics operates with a focus on developing precision medicines for severe genetic diseases. Key aspects of their operational framework include:

• Target Identification and Validation: Stoke uses its TANGO platform to identify genes where increasing protein production can address the underlying cause of disease.
• Drug Development: Focuses on antisense oligonucleotide (ASO) therapeutics.
• Clinical Trials: Stoke conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Partnerships and Collaborations: Stoke may collaborate with other companies or research institutions to advance its programs.

Stoke Therapeutics' Strategic Advantages

Stoke Therapeutics' strategic advantages stem from its innovative technology and focused approach:

• TANGO Platform: A proprietary platform that enables the company to identify and develop ASO medicines for a range of genetic diseases.
• Focus on Upregulation: Stoke's approach of upregulating protein expression offers a unique way to treat diseases caused by insufficient protein production.
• Targeting RNA: By targeting RNA, Stoke's ASO medicines can modulate protein expression with high precision.
• Pipeline Depth: Stoke has a pipeline of programs targeting a range of genetic diseases, with the lead program focused on Dravet syndrome.

For more insights into stakeholders, consider reading: Exploring Stoke Therapeutics, Inc. (STOK) Investor Profile: Who’s Buying and Why?

Stoke Therapeutics, Inc. (STOK) How It Makes Money

Stoke Therapeutics, Inc. operates as a biotechnology company, primarily focused on developing treatments for genetic diseases by precisely upregulating protein expression. The company generates revenue primarily through collaborative agreements and licensing arrangements with pharmaceutical partners, as they have no products approved for sale yet.

Stoke Therapeutics, Inc.'s Revenue Breakdown

As a clinical-stage biotechnology company, Stoke Therapeutics' revenue streams are currently centered around collaborations and licensing agreements, as they do not have products on the market. The following table provides a breakdown of their revenue composition:

Stoke Therapeutics, Inc.'s Business Economics

Stoke Therapeutics' business economics are characterized by significant investment in research and development (R&D). Key aspects include:

• R&D Expenses: A substantial portion of their operating expenses is dedicated to advancing their TANGO (Targeted Augmentation of Nuclear Gene Output) platform and pipeline programs.
• Collaboration Agreements: Revenue from partnerships helps to offset R&D costs and provides capital for further development.
• Intellectual Property: Strong patent protection is crucial for maintaining a competitive advantage and attracting potential partners.
• Clinical Trial Success: The success of clinical trials is paramount for future revenue generation through potential drug approvals and commercialization.

Stoke Therapeutics, Inc.'s Financial Performance

Stoke Therapeutics' financial performance can be assessed through the following key points:

• Cash Reserves: Maintaining a strong cash position is vital to fund ongoing research and development activities. As of December 31, 2024, Stoke Therapeutics reported cash, cash equivalents, and investments of $246.1 million.
• Operating Expenses: Operating expenses consist primarily of research and development expenses and general and administrative expenses. For the year 2024, R&D expenses were $134.1 million, while general and administrative expenses totaled $34.9 million.
• Net Loss: As a development-stage company, Stoke Therapeutics typically incurs net losses. For 2024, the company reported a net loss of $140.8 million, or $2.70 per share.
• Revenue: Stoke Therapeutics reported collaboration revenue of $28.2 million for the year ended December 31, 2024.

To gain more insights into Stoke Therapeutics' financial health, you might find this resource helpful: Breaking Down Stoke Therapeutics, Inc. (STOK) Financial Health: Key Insights for Investors

Stoke Therapeutics, Inc. (STOK) Market Position & Future Outlook

Stoke Therapeutics is strategically positioned to advance in the biotechnology sector, particularly in addressing severe genetic diseases through its TANGO (Targeted Augmentation of Nuclear Gene Output) platform. The company's future success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.

Competitive Landscape

Opportunities & Challenges

Industry Position

Stoke Therapeutics operates within the competitive landscape of genetic disease therapeutics, focusing on innovative RNA-based therapies. Key aspects of their industry position include:

• Novel Technology: Stoke's TANGO platform represents a unique approach to treating genetic diseases by upregulating gene expression.
• Targeted Therapies: Focus on specific genetic disorders allows for targeted drug development and potential for high efficacy.
• Market Niche: Addressing rare and severe genetic diseases positions Stoke in a niche market with less competition but significant unmet needs.

To gain more insights into the company's guiding principles, visit: Mission Statement, Vision, & Core Values of Stoke Therapeutics, Inc. (STOK).